Table 9.
Variable | Day 0 | Day 84 | Within Group p-Value | Between Group p-Value |
---|---|---|---|---|
Human COMP (×100 ng/mL) | ||||
Placebo | 4280.4 (±1037.8) | 4577.8 (±1498.7) | 0.195 | 0.091 |
AF1 | 4151.0 (±1186.6) | 3818.9 (±1171.4) | 0.092 | |
AF2 | 4229.5 (±1339.9) | 4303.0 (±1387.6) | 0.700 | |
AF1 + AF2 | 4191.7 (±1258.4) | 4069.6 (±1296.4) | 0.371 | |
TNF-alpha (pg/mL) | ||||
Placebo | 38.9 (±26.3) | 37.2 (±22.2) | 0.733 | 0.492 |
AF1 | 51.7 (±35.6) | 49.5 (±37.3) | 0.641 | |
AF2 | 47.5 (±26.3) | 39.4 (±25.5) | 0.026 | |
AF1 + AF2 | 49.5 (±30.1) | 44.3 (±31.9) | 0.074 | |
C-Reactive Protein (mg/L) | ||||
Placebo | 2.5 (±1.8) | 1.7 (±1.5) | 0.044 | 0.137 |
AF1 | 2.5 (±2.7) | 2.5 (±3.1) | 0.909 | |
AF2 | 2.3 (±2.2) | 2.0 (±1.9) | 0.249 | |
AF1 + AF2 | 2.3 (±2.4) | 2.2 (±2.5) | 0.619 |
Values Presented as Mean ± Standard Deviation
Values determined to be significant (p = <0.05) indicated